Clinically significant developments in RCC presented at ASCO GU, including insights into the growing importance of HIF-2α inhibition, are discussed by Dr Brian Rini of Vanderbilt University.
Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in ...
The 2026 European Association of Urology (EAU) annual meeting featured a managing advanced disease in renal and rare cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results